Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Cash from Operations (2018 - 2023)

Endonovo Therapeutics has reported Cash from Operations over the past 12 years, most recently at 65367.0 for Q3 2023.

  • Quarterly results put Cash from Operations at 65367.0 for Q3 2023, up 47.23% from a year ago — trailing twelve months through Sep 2023 was 629904.0 (up 25.42% YoY), and the annual figure for FY2022 was 678838.0, up 31.19%.
  • Cash from Operations for Q3 2023 was 65367.0 at Endonovo Therapeutics, up from 138996.0 in the prior quarter.
  • Over the last five years, Cash from Operations for ENDV hit a ceiling of 65367.0 in Q3 2023 and a floor of 1016770.0 in Q3 2019.
  • Median Cash from Operations over the past 5 years was 200000.0 (2023), compared with a mean of 281704.32.
  • Biggest five-year swings in Cash from Operations: skyrocketed 90.49% in 2020 and later crashed 102.9% in 2021.
  • Endonovo Therapeutics' Cash from Operations stood at 308381.0 in 2019, then soared by 37.46% to 192856.0 in 2020, then crashed by 102.9% to 391296.0 in 2021, then soared by 42.36% to 225541.0 in 2022, then soared by 71.02% to 65367.0 in 2023.
  • The last three reported values for Cash from Operations were 65367.0 (Q3 2023), 138996.0 (Q2 2023), and 200000.0 (Q1 2023) per Business Quant data.